相似文献
1
Recombinant rabies virus as potential live-viral vaccines for HIV-1.
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3544-9. doi: 10.1073/pnas.97.7.3544.
2
Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7777-81. doi: 10.1073/pnas.89.16.7777.
3
Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.
J Virol. 2001 May;75(9):4430-4. doi: 10.1128/JVI.75.9.4430-4434.2001.
4
Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells.
J Virol. 2002 Jan;76(1):19-31. doi: 10.1128/jvi.76.1.19-31.2002.
5
Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
PLoS One. 2013 Oct 1;8(10):e78521. doi: 10.1371/journal.pone.0078521. eCollection 2013.
6
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
J Infect Dis. 1998 May;177(5):1230-46. doi: 10.1086/515288.
7
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2019-35. doi: 10.1089/088922200750054756.
8
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
J Virol. 1997 Jun;71(6):4319-30. doi: 10.1128/JVI.71.6.4319-4330.1997.
9
Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.
J Virol. 2001 Sep;75(18):8724-32. doi: 10.1128/jvi.75.18.8724-8732.2001.
10
Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.
J Virol. 2011 Oct;85(20):10529-41. doi: 10.1128/JVI.05050-11. Epub 2011 Aug 17.
引用本文的文献
1
Rabies virus as vector for development of vaccine: pros and cons.
Front Vet Sci. 2024 Sep 25;11:1475431. doi: 10.3389/fvets.2024.1475431. eCollection 2024.
2
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.
Heliyon. 2024 Jul 20;10(15):e34927. doi: 10.1016/j.heliyon.2024.e34927. eCollection 2024 Aug 15.
3
Interleukin-25 enhances humoral immune responses caused by the rabies virus.
Virulence. 2022 Dec;13(1):1446-1454. doi: 10.1080/21505594.2022.2116146.
4
Self-replicating vehicles based on negative strand RNA viruses.
Cancer Gene Ther. 2023 Jun;30(6):771-784. doi: 10.1038/s41417-022-00436-7. Epub 2022 Feb 15.
5
Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats.
Vaccines (Basel). 2020 Nov 13;8(4):680. doi: 10.3390/vaccines8040680.
6
A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes.
Med Sci Monit. 2020 May 28;26:e926016. doi: 10.12659/MSM.926016.
7
Incorporating B cell activating factor (BAFF) into the membrane of rabies virus (RABV) particles improves the speed and magnitude of vaccine-induced antibody responses.
PLoS Negl Trop Dis. 2019 Nov 14;13(11):e0007800. doi: 10.1371/journal.pntd.0007800. eCollection 2019 Nov.
8
Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
PLoS One. 2019 Oct 7;14(10):e0223684. doi: 10.1371/journal.pone.0223684. eCollection 2019.
9
Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV.
Vaccines (Basel). 2019 Sep 19;7(3):119. doi: 10.3390/vaccines7030119.
10
Rabies-based vaccine induces potent immune responses against Nipah virus.
NPJ Vaccines. 2019 Apr 15;4:15. doi: 10.1038/s41541-019-0109-5. eCollection 2019.
本文引用的文献
1
HIV disease treatment in the era of HAART.
Biomed Pharmacother. 1999 Mar;53(2):93-105. doi: 10.1016/s0753-3322(99)80066-3.
2
Virus promoters determine interference by defective RNAs: selective amplification of mini-RNA vectors and rescue from cDNA by a 3' copy-back ambisense rabies virus.
J Virol. 1999 May;73(5):3818-25. doi: 10.1128/JVI.73.5.3818-3825.1999.
3
The use of combination antiretroviral therapy in HIV-infected patients.
Ann Pharmacother. 1999 Feb;33(2):198-209. doi: 10.1345/aph.18145.
4
Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques.
Nat Med. 1999 Feb;5(2):194-203. doi: 10.1038/5557.
5
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
AIDS. 1998 Dec 24;12(18):2407-15. doi: 10.1097/00002030-199818000-00009.
6
Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter.
J Virol. 1999 Jan;73(1):251-9. doi: 10.1128/JVI.73.1.251-259.1999.
7
Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV.
AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S291-8.
8
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.
J Virol. 1998 Sep;72(9):7620-5. doi: 10.1128/JVI.72.9.7620-7625.1998.
9
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
J Infect Dis. 1998 May;177(5):1230-46. doi: 10.1086/515288.
10
Six decades of vaccine development--a personal history.
Nat Med. 1998 May;4(5 Suppl):507-14. doi: 10.1038/nm0598supp-507.
Zotero 插件